

# Sonia Hernández-Díaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10923175/publications.pdf>

Version: 2024-02-01

100  
papers

14,082  
citations

38720

50  
h-index

33869

99  
g-index

102  
all docs

102  
docs citations

102  
times ranked

13987  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Structural Approach to Selection Bias. <i>Epidemiology</i> , 2004, 15, 615-625.	1.2	2,017
2	Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. <i>American Journal of Epidemiology</i> , 2002, 155, 176-184.	1.6	1,107
3	Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. <i>New England Journal of Medicine</i> , 2006, 354, 2443-2451.	13.9	1,100
4	Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. <i>New England Journal of Medicine</i> , 2006, 354, 579-587.	13.9	821
5	Folic Acid Antagonists during Pregnancy and the Risk of Birth Defects. <i>New England Journal of Medicine</i> , 2000, 343, 1608-1614.	13.9	689
6	Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 51.e1-51.e8.	0.7	587
7	First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. <i>New England Journal of Medicine</i> , 2007, 356, 2675-2683.	13.9	467
8	Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 70-75.	2.4	449
9	Beyond the intention-to-treat in comparative effectiveness research. <i>Clinical Trials</i> , 2012, 9, 48-55.	0.7	348
10	Use of over-the-counter medications during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 771-777.	0.7	331
11	The Birth Weight "Paradox" Uncovered?. <i>American Journal of Epidemiology</i> , 2006, 164, 1115-1120.	1.6	303
12	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. <i>New England Journal of Medicine</i> , 2014, 370, 2397-2407.	13.9	296
13	Increase in Prescription Opioid Use During Pregnancy Among Medicaid-Enrolled Women. <i>Obstetrics and Gynecology</i> , 2014, 123, 997-1002.	1.2	291
14	Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. <i>JAMA Psychiatry</i> , 2016, 73, 938.	6.0	206
15	Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. <i>JAMA Neurology</i> , 2015, 72, 981.	4.5	201
16	Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2142.	3.8	198
17	Lithium Use in Pregnancy and the Risk of Cardiac Malformations. <i>New England Journal of Medicine</i> , 2017, 376, 2245-2254.	13.9	183
18	Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States. <i>Anesthesiology</i> , 2014, 120, 1216-1224.	1.3	180

#	ARTICLE	IF	CITATIONS
19	Statins and congenital malformations: cohort study. <i>BMJ, The</i> , 2015, 350, h1035-h1035.	3.0	172
20	Risk Factors for Persistent Pulmonary Hypertension of the Newborn. <i>Pediatrics</i> , 2007, 120, e272-e282.	1.0	163
21	Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2016, 173, 263-270.	4.0	162
22	Algorithms to estimate the beginning of pregnancy in administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 16-24.	0.9	154
23	Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1013-1018.	0.9	140
24	Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. <i>PLoS ONE</i> , 2013, 8, e67405.	1.1	140
25	Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. <i>BMJ, The</i> , 2015, 350, h2102-h2102.	3.0	140
26	National trends in antidepressant medication treatment among publicly insured pregnant women. <i>General Hospital Psychiatry</i> , 2013, 35, 265-271.	1.2	135
27	Incidence of serious upper gastrointestinal bleeding/perforation in the general population. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 157-163.	2.4	131
28	Use of topiramate in pregnancy and risk of oral clefts. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 405.e1-405.e7.	0.7	130
29	Randomized Trials Analyzed as Observational Studies. <i>Annals of Internal Medicine</i> , 2013, 159, 560-2.	2.0	125
30	Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008. <i>PLoS ONE</i> , 2012, 7, e36171.	1.1	104
31	The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program. <i>Obstetrics and Gynecology</i> , 2015, 126, 465-473.	1.2	104
32	Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. <i>BMJ: British Medical Journal</i> , 2017, 358, j3326.	2.4	104
33	Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. <i>BMJ, The</i> , 2013, 347, f4877-f4877.	3.0	94
34	Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations. <i>JAMA Psychiatry</i> , 2018, 75, 167.	6.0	93
35	Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2429.	3.8	90
36	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. <i>American Journal of Psychiatry</i> , 2009, 166, 320-328.	4.0	89

#	ARTICLE	IF	CITATIONS
37	Late Pregnancy $\beta$ Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. <i>Pediatrics</i> , 2016, 138, .	1.0	89
38	Validity of maternal and infant outcomes within nationwide Medicaid data. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 646-655.	0.9	81
39	Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 906-922.	0.9	79
40	Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. <i>Obstetrics and Gynecology</i> , 2017, 129, 174-184.	1.2	77
41	Risk of Gestational Hypertension in Relation to Folic Acid Supplementation during Pregnancy. <i>American Journal of Epidemiology</i> , 2002, 156, 806-812.	1.6	76
42	Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. <i>Paediatric and Perinatal Epidemiology</i> , 2009, 23, 18-28.	0.8	70
43	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 555-560.	0.7	70
44	$\beta$ -Blocker Use in Pregnancy and the Risk for Congenital Malformations. <i>Annals of Internal Medicine</i> , 2018, 169, 665.	2.0	65
45	Nonsteroidal Antiinflammatory Drugs in Late Pregnancy and Persistent Pulmonary Hypertension of the Newborn. <i>Pediatrics</i> , 2013, 131, 79-87.	1.0	64
46	Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 337.e1-337.e14.	0.7	63
47	Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. <i>American Journal of Psychiatry</i> , 2018, 175, 564-574.	4.0	61
48	Use of Decongestants During Pregnancy and the Risk of Birth Defects. <i>American Journal of Epidemiology</i> , 2013, 178, 198-208.	1.6	59
49	Case-Crossover and Case-Time-Control Designs in Birth Defects Epidemiology. <i>American Journal of Epidemiology</i> , 2003, 158, 385-391.	1.6	57
50	Estimating Absolute Risks in the Presence of Nonadherence. <i>Epidemiology</i> , 2010, 21, 528-539.	1.2	57
51	Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 335-342.	0.9	56
52	Positive predictive value of computerized records for major congenital malformations. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 455-460.	0.9	51
53	Placental Complications Associated With Psychostimulant Use in Pregnancy. <i>Obstetrics and Gynecology</i> , 2017, 130, 1192-1201.	1.2	50
54	Good practices for the design, analysis, and interpretation of observational studies on birth spacing and perinatal health outcomes. <i>Paediatric and Perinatal Epidemiology</i> , 2019, 33, O15-O24.	0.8	49

#	ARTICLE	IF	CITATIONS
55	Patterns of Outpatient Antihypertensive Medication Use During Pregnancy in a Medicaid Population. <i>Hypertension</i> , 2012, 60, 913-920.	1.3	48
56	Is there a direct effect of pre-eclampsia on cerebral palsy not through preterm birth?. <i>Paediatric and Perinatal Epidemiology</i> , 2011, 25, 111-115.	0.8	46
57	From causal diagrams to birth weight-specific curves of infant mortality. <i>European Journal of Epidemiology</i> , 2008, 23, 163-166.	2.5	38
58	Antibiotics and oral contraceptive failure – a case-crossover study. <i>Contraception</i> , 2011, 83, 418-425.	0.8	37
59	Invited Commentary: Composite Outcomes as an Attempt to Escape From Selection Bias and Related Paradoxes. <i>American Journal of Epidemiology</i> , 2014, 179, 368-370.	1.6	34
60	Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants. <i>Reproductive Toxicology</i> , 2014, 47, 111-114.	1.3	33
61	Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 934-942.	0.9	33
62	Assessment of Antihistamine Use in Early Pregnancy and Birth Defects. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 666-674.e1.	2.0	32
63	Prenatal Treatment and Outcomes of Women With Opioid Use Disorder. <i>Obstetrics and Gynecology</i> , 2018, 132, 916-922.	1.2	31
64	Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials. <i>Journal of Clinical Epidemiology</i> , 2018, 103, 10-21.	2.4	30
65	Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. <i>New England Journal of Medicine</i> , 2014, 371, 1167-1169.	13.9	29
66	Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. <i>American Journal of Psychiatry</i> , 2018, 175, 1225-1231.	4.0	28
67	Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. <i>BMJ, The</i> , 2020, 368, m237.	3.0	28
68	Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. <i>PLoS Medicine</i> , 2020, 17, e1003322.	3.9	27
69	Quantification of selection bias in studies of risk factors for birth defects among livebirths. <i>Paediatric and Perinatal Epidemiology</i> , 2020, 34, 655-664.	0.8	27
70	Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. <i>BMJ, The</i> , 2021, 372, n102.	3.0	26
71	iatrogenic legacy from diethylstilbestrol exposure. <i>Lancet, The</i> , 2002, 359, 1081-1082.	6.3	24
72	Challenges of using primary care electronic medical records in the UK to study medications in pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 977-985.	0.9	24

#	ARTICLE	IF	CITATIONS
73	Dietary Folate and the Risk of Nonfatal Myocardial Infarction. <i>Epidemiology</i> , 2002, 13, 700-706.	1.2	23
74	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders. <i>JAMA Internal Medicine</i> , 2022, 182, 522.	2.6	22
75	The Effect of Prenatal Treatments on Offspring Events in the Presence of Competing Events. <i>Epidemiology</i> , 2020, 31, 636-643.	1.2	20
76	First Trimester Exposure to Antiretroviral Therapy and Risk of Birth Defects. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 741-746.	1.1	19
77	Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. <i>BMJ</i> , The, 2020, 369, m1494.	3.0	17
78	Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Gestational Hypertension. <i>Epidemiology</i> , 2005, 16, 628-634.	1.2	16
79	Prescription of medications during pregnancy: accidents, compromises, and uncertainties. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 613-617.	0.9	15
80	Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. <i>Obstetrics and Gynecology</i> , 2015, 126, 271-278.	1.2	15
81	Validity of claims-based algorithms to identify neurodevelopmental disorders in children. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1635-1642.	0.9	14
82	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with three-group matching weights. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 182-190.	0.9	13
83	Zidovudine use in pregnancy and congenital malformations. <i>Aids</i> , 2017, 31, 1733-1743.	1.0	12
84	Can folic acid protect against congenital heart defects in down syndrome?. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2006, 76, 714-717.	1.6	10
85	Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1653-1662.	1.1	10
86	Invited Commentary: Simple Models for a Complicated Reality. <i>American Journal of Epidemiology</i> , 2006, 164, 312-314.	1.6	8
87	Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine. <i>Cephalalgia</i> , 2021, 41, 392-403.	1.8	8
88	Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. <i>Human Reproduction</i> , 2022, 37, 793-805.	0.4	8
89	Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims. <i>Fertility and Sterility</i> , 2022, 117, 981-991.	0.5	8
90	Chronic prescription opioid use in pregnancy in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 504-513.	0.9	7

#	ARTICLE	IF	CITATIONS
91	International Registry of Coronavirus Exposure in Pregnancy (IRCEP) – Cohort Description and Methodological Considerations. American Journal of Epidemiology, 2022, , .	1.6	7
92	Ischemic Placental Disease, Preterm Delivery, and Their Association With Opioid Use During Pregnancy. American Journal of Epidemiology, 2022, 191, 759-768.	1.6	6
93	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	0.9	6
94	Name of the Bias and Sex of the Angels. Epidemiology, 2011, 22, 232-233.	1.2	5
95	The Impact of Technology on the Diagnosis of Congenital Malformations. American Journal of Epidemiology, 2019, 188, 1892-1901.	1.6	5
96	Using nationally representative survey data for external adjustment of unmeasured confounders: An example using the NHANES data. Pharmacoepidemiology and Drug Safety, 2020, 29, 1151-1158.	0.9	4
97	In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1596-1604.	0.9	4
98	Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome. American Journal of Epidemiology, 2022, 191, 208-219.	1.6	4
99	Toh et al. Respond to "Compromise or Compromising?". American Journal of Epidemiology, 2007, 167, 644-645.	1.6	1
100	Reply. Obstetrics and Gynecology, 2014, 124, 638.	1.2	0